InBody has outlined strategies to enhance hospital competitiveness in response to the growing use of GLP-1 obesity treatments. As the focus shifts from simple weight loss to maintaining muscle mass while achieving healthy weight reduction, comprehensive management of body composition changes, including skeletal muscle mass, body fat, body water, and phase angle, is gaining attention in medical settings.
On July 23, InBody, in collaboration with the medical platform Medistaff, held a webinar titled 'In the Era of Obesity Treatments, How Will Hospitals Survive?'
The webinar addressed the rapidly changing landscape of the GLP-1 treatment market. With increased accessibility to drug therapies due to price reductions, diversification of formulations such as oral and patch forms, expanded indications for metabolic diseases, and broader international coverage, the importance of precise monitoring and ongoing patient management was emphasized.
InBody proposed a shift from traditional body mass index (BMI) assessments to diagnostics based on body composition analysis. Internal medicine, family medicine, and orthopedics are expanding their focus to include body fat reduction, pain management, and post-treatment care. Dermatology and plastic surgery are also adopting differentiated strategies by utilizing body composition data for managing side effects and patient education, according to the company.
Particularly highlighted was the significance of body water indicators in interpreting weight changes. A reduction in body water can be misinterpreted as muscle loss, underscoring the need to evaluate muscle mass, body fat, body water, and nutritional status together.
The following session introduced the clinical application of phase angle, a cellular health indicator. Phase angle, which translates the resistance of cell membranes into an angle, indicates that a higher value reflects better membrane stability and health. InBody explained that even without significant changes in muscle mass or body fat, monitoring phase angle and extracellular water ratio can provide early insights into cellular-level changes.
An InBody representative stated, "As the medical field rapidly evolves with the spread of GLP-1 treatments, precise monitoring based on body composition analysis will be the solution. We aim to enhance the accuracy of prescriptions and the level of patient management based on global clinical data and technology."
Meanwhile, a report from market research firm GlobalData predicts that the global market for GLP-1 treatments will grow from approximately $30 billion in 2023 to $125 billion by 2033, with an average annual growth rate of 15%.
On July 23, InBody, in collaboration with the medical platform Medistaff, held a webinar titled 'In the Era of Obesity Treatments, How Will Hospitals Survive?'
The webinar addressed the rapidly changing landscape of the GLP-1 treatment market. With increased accessibility to drug therapies due to price reductions, diversification of formulations such as oral and patch forms, expanded indications for metabolic diseases, and broader international coverage, the importance of precise monitoring and ongoing patient management was emphasized.
InBody proposed a shift from traditional body mass index (BMI) assessments to diagnostics based on body composition analysis. Internal medicine, family medicine, and orthopedics are expanding their focus to include body fat reduction, pain management, and post-treatment care. Dermatology and plastic surgery are also adopting differentiated strategies by utilizing body composition data for managing side effects and patient education, according to the company.
Particularly highlighted was the significance of body water indicators in interpreting weight changes. A reduction in body water can be misinterpreted as muscle loss, underscoring the need to evaluate muscle mass, body fat, body water, and nutritional status together.
The following session introduced the clinical application of phase angle, a cellular health indicator. Phase angle, which translates the resistance of cell membranes into an angle, indicates that a higher value reflects better membrane stability and health. InBody explained that even without significant changes in muscle mass or body fat, monitoring phase angle and extracellular water ratio can provide early insights into cellular-level changes.
An InBody representative stated, "As the medical field rapidly evolves with the spread of GLP-1 treatments, precise monitoring based on body composition analysis will be the solution. We aim to enhance the accuracy of prescriptions and the level of patient management based on global clinical data and technology."
Meanwhile, a report from market research firm GlobalData predicts that the global market for GLP-1 treatments will grow from approximately $30 billion in 2023 to $125 billion by 2033, with an average annual growth rate of 15%.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.